GFAP and COVID-19: In contrast, in a longitudinal analysis of blood GFAP- and NfL-levels of COVID-19 patients, normal levels were noted 6 months after acute SARS-CoV-2 infection following an initial peak, although half of the patients reported persistent neurological symptoms17.